Media Pack
News

Current Edition

Volume 7 issue 1

Upcoming Events

 
 

Advertisement

 
news

Pfizer to acquire Biohaven in $11.6B bet on biotech’s migraine drugs

Pfizer has agreed to acquire Biohaven Pharmaceuticals for $11.6 billion in a deal that turns an existing alliance on a fast-selling migraine drug into a big bet on it...
13 May 2022 news Biohaven | Drugs
Continue Reading →
news

Novartis suspends production of two radiopharmaceutical drugs over quality concerns

Dive Brief: Novartis has suspended production of two cancer drugs at plants in Italy and New Jersey due to “potential quality issues” it identified in its manufact...
9 May 2022 news cancer | Drugs
Continue Reading →
news

FDA panel supports agency push to raise approval bar for certain cancer drugs

The Food and Drug Administration appears ready to raise its approval standards for a well-known class of cancer drugs due to concerns they aren't helping patients liv...
25 April 2022 news blood | cancer
Continue Reading →
news

Civica targets insulin in effort to produce cheaper drugs

Dive Brief: Civica is making plans to offer three versions of insulin that can be sold at dramatically lower prices than today's alternatives, targeting a need hig...
7 March 2022 news cheaper | Civica
Continue Reading →
news

Amgen partners with Arrakis to develop drugs aimed at RNA

Dive Brief: Amgen will team with Arrakis Therapeutics to develop oral drugs that target and destroy RNA, announcing a deal Tuesday that will pay the Waltham, Massa...
14 January 2022 news AstraZeneca | Drugs
Continue Reading →
news

Novartis to consider sale or separation of Sandoz business

Under CEO Vas Narasimhan, Novartis has slimmed down what was a sprawling conglomerate spanning prescription and generic drugs, eye care and consumer healthcare. The d...
29 October 2021 news Business | Drugs
Continue Reading →
Volume 4 Issue 3

4 Drugs Facing Key Patent Expirations and Potential Generic Entry From September 2021–November 2021

A challenge in anticipating generic entry is elucidating which patents and regulatory protections constrain generic entry. Yali Friedman at DrugPatentWatch presents a...
1 September 2021 Volume 4 Issue 3 Drug Patent | Drugs
Continue Reading →
news

Blood test to determine best timing to administer drugs

 The team based its research on the fact that the efficacy of drugs changes depending on what time of day they are administered. A team of researchers at the Charit...
6 July 2018 news administer | best
Continue Reading →
news

PhRMA criticizes ICER in latest skirmish over valuing drugs

Industry lobbying group PhRMA on Thursday warned the use of cost-effectiveness estimates like those developed by the Institute for Clinical and Economic Review co...
1 June 2018 news Drugs | ICER
Continue Reading →
news

For Expensive New Drugs, Biopharma Should Make Money-Back Guarantees Mandatory

In a recent paper on “Value-Based Pricing for Drugs”, authors Anna Kaltenboeck and Peter B. Bach of the Memorial Sloan Kettering Cancer Center discuss the high cost o...
3 May 2018 news biopharma | Drugs
Continue Reading →
 
IBI-white.png

International Biopharmaceutical Industry

IBI – International Biopharmaceutical Industry was established to fill in the void for effective marketing and communication between all stakeholders in the Life sciences sector globally.

Facebook Linkedin
Bio Pharmaceutical Media © 2024, All Rights Reserved – Powered by Teksyte